| The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ... Nature 575 (7781), 217-223, 2019 | 1694 | 2019 |
| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 1284 | 2020 |
| Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis BE Houk, CL Bello, B Poland, LS Rosen, GD Demetri, RJ Motzer Cancer chemotherapy and pharmacology 66, 357-371, 2010 | 554 | 2010 |
| A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients BE Houk, CL Bello, D Kang, M Amantea Clinical Cancer Research 15 (7), 2497-2506, 2009 | 275 | 2009 |
| A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety H Uemura, N Shinohara, T Yuasa, Y Tomita, H Fujimoto, M Niwakawa, ... Japanese journal of clinical oncology 40 (3), 194-202, 2010 | 168 | 2010 |
| A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas A Rajan, RJ Kelly, JB Trepel, YS Kim, SV Alarcon, S Kummar, M Gutierrez, ... Clinical Cancer Research 17 (21), 6831-6839, 2011 | 145 | 2011 |
| A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors SF Jones, LL Siu, JC Bendell, JM Cleary, ARA Razak, JR Infante, ... Investigational new drugs 33, 1100-1107, 2015 | 129 | 2015 |
| Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma Y Tomita, N Shinohara, T Yuasa, H Fujimoto, M Niwakawa, S Mugiya, ... Japanese journal of clinical oncology 40 (12), 1166-1172, 2010 | 128 | 2010 |
| Kinetic modeling of plasmid DNA degradation in rat plasma BE Houk, G Hochhaus, JA Hughes AAPS PharmSci 1, 15-20, 1999 | 119 | 1999 |
| First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer GI Shapiro, KM Bell-McGuinn, JR Molina, J Bendell, J Spicer, EL Kwak, ... Clinical Cancer Research 21 (8), 1888-1895, 2015 | 118 | 2015 |
| Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach BE Houk, CL Bello, MD Michaelson, RM Bukowski, BG Redman, ... Journal of Clinical Oncology 25 (18_suppl), 5027-5027, 2007 | 84 | 2007 |
| A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer JM Del Campo, M Birrer, C Davis, K Fujiwara, A Gollerkeri, M Gore, ... Gynecologic oncology 142 (1), 62-69, 2016 | 83 | 2016 |
| Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer CD Britten, AA Adjei, R Millham, BE Houk, G Borzillo, K Pierce, ... Investigational new drugs 32, 510-517, 2014 | 81 | 2014 |
| A multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer ZA Wainberg, M Alsina, HP Soares, I Braña, CD Britten, G Del Conte, ... Targeted oncology 12, 775-785, 2017 | 80 | 2017 |
| Pharmacokinetics of plasmid DNA in the rat BE Houk, R Martin, G Hochhaus, JA Hughes Pharmaceutical research 18, 67-74, 2001 | 71 | 2001 |
| PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST EK Hansson, MA Amantea, P Westwood, PA Milligan, BE Houk, J French, ... CPT: pharmacometrics & systems pharmacology 2 (11), 1-9, 2013 | 68 | 2013 |
| Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies N Reddy, PM Voorhees, BE Houk, N Brega, JM Hinson Jr, A Jillela Clinical Lymphoma Myeloma and Leukemia 13 (4), 385-391, 2013 | 45 | 2013 |
| Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers C Bello, B Houk, L Sherman, S Misbah, N Sarapa, J Smeraglia, X Haung Journal of Clinical Oncology 23 (16_suppl), 3078-3078, 2005 | 30 | 2005 |
| Standard error of empirical Bayes estimate in NONMEM® VI D Kang, KS Bae, BE Houk, RM Savic, MO Karlsson The Korean journal of physiology & pharmacology: official journal of the …, 2012 | 27 | 2012 |
| Discovery of 2, 4-bis-arylamino-1, 3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors JL Buchanan, JR Newcomb, DP Carney, SC Chaffee, L Chai, R Cupples, ... Bioorganic & medicinal chemistry letters 21 (8), 2394-2399, 2011 | 27 | 2011 |
